Join us for a fascinating conversation with Dr. Subhoja Chakraborty from the University of Central Florida, whose cutting-edge research targets the global challenge of malaria drug resistance. Dr. Chakraborty shares her journey from structure-based drug design during her PhD to her recent collaborative work repurposing human kinase inhibitors as rapid, selective antimalarials against drug-resistant Plasmodium falciparum strains.<h4>In this episode, you'll learn:</h4><ul><li>How structure-guided approaches reveal potential drug targets, including cysteine proteases like falcipain-2, and kinases implicated in malaria's complex life cycle.</li><li>The power of repurposing kinase inhibitors originally developed for cancer and other diseases, focusing on compound 12, which blocks hemozoin formation and protein kinase 6—key steps in parasite survival.</li><li>Lab techniques such as affinity, gel filtration, and size exclusion chromatography for recombinant protein purification—and how troubleshooting is crucial for high-yield, stable complexes.</li><li>Advances in mass spectrometry for characterizing protein interactions, validating drug targets, and mapping molecular pathways pivotal to malaria therapeutics.</li><li>Tips and lessons for new researchers facing the challenges of sample preparation, complex protocols, and working as part of a collaborative team.</li></ul>Dr. Chakraborty’s insights bridge the gap between basic science and translational drug discovery, offering hope for more effective, targeted malaria treatments in a world where resistance to frontline therapies threatens millions.<h4>Referenced Papers:</h4><ul><li>"Plasmodium falciparum protein kinase 6 and hemozoin formation are inhibited by a type II human kinase inhibitor exhibiting antimalarial activity" (Cell Chemical Biology, 2025)</li><li>"New insights of falcipain 2 structure from Plasmodium falciparum 3D7 strain" (BBRC, 2022)</li><li>"Structure-Based Optimization of Protease−Inhibitor Interactions to Enhance Specificity of Human Stefin‑A against Falcipain‑2 from the Plasmodium falciparum 3D7 Strain" (Biochemistry, 2023)</li></ul>If you’re a student, scientist, or simply passionate about advances in infectious disease research, this episode offers actionable insights, inspiring advice, and a front-row seat to innovation in combating malaria.<h3>Video Transcription</h3><h4>From Structural Biology to Drug Discovery: Chromatography and Mass Spectrometry in Malaria Research</h4><h5>Introduction</h5>In this discussion, Subhoja shares insights into her research journey, focusing on malaria drug discovery and the role of modern analytical techniques in biological and biomedical research. The conversation is aimed primarily at undergraduate students and early-career researchers interested in chemistry, biotechnology, and life sciences.<h5>Research Focus: Malaria Drug Discovery and Kinase Targets</h5>Subhoja is currently involved in malaria drug discovery research at the University of Central Florida, where she has been working since beginning her postdoctoral position two years ago. Her earlier PhD research focused on structure-based drug design in malaria, using a combination of in silico approaches, recombinant protein expression, and X-ray crystallography to determine precise three-dimensional structures of target proteins and their inhibitors.This structural perspective provided a foundation for her current work, which centers on drug discovery through compound screening and repurposing. A recent publication from her laboratory explores the use of repurposed mammalian CDK-like kinase inhibitors as potential antimalarial agents. While such kinase inhibitors are well known in cancer and cardiovascular research, their application to malaria targets represents a novel and promising approach.Kinases are attractive drug targets because of their central role in cell signaling and growth pathways. By targeting specific kinases involved in different stages of the malaria parasite life cycle—whether asexual growth, gametocytogenesis, or differentiation—it may be possible to significantly inhibit parasite growth and progression.<h5>Chromatography in Protein Expression and Purification Workflows</h5>Chromatography plays a critical role throughout Subhoja’s research. Her experience spans from basic chromatography techniques during her early training to advanced protein purification workflows using affinity chromatography, gel filtration (size exclusion chromatography), and ion exchange chromatography.Recombinant proteins are routinely purified using affinity resins such as nickel or cobalt, followed by further purification to remove contaminants. Fast Protein Liquid Chromatography (FPLC) enables compact, stepwise purification workflows suitable for producing proteins for in vitro assays.A recurring challenge in this process is the expression of high-molecular-weight proteins, which often accumulate in insoluble fractions or inclusion bodies. Careful selection of expression vectors, host systems, and induction conditions is therefore essential to maximize yield and solubility.<h5>Integrating Size Exclusion Chromatography into the Workflow</h5>Size exclusion chromatography (SEC) is typically used after affinity purification to further improve protein purity. Following elution with imidazole or glutathione, desalting is required to prevent buffer components from interfering with downstream assays. This is often achieved using desalting columns such as G-25 or PD-10.To remove lower-molecular-weight contaminants, finer SEC media—such as Superdex or Sephacryl columns—are employed. Concentration steps using molecular-weight cut-off filters are then applied to obtain the desired protein concentration for functional studies.These iterative purification and troubleshooting steps are a routine part of protein biochemistry and reflect the importance of methodical optimization and careful validation.<h5>The Role of Mass Spectrometry in Biomolecular Characterization</h5>Mass spectrometry is a key analytical tool in Subhoja’s research pipeline, particularly for target identification and validation. In both malaria and cancer research, MS is used alongside chromatography, immunoprecipitation, and pull-down assays to study protein interactions and molecular recognition events.Affinity-based mass spectrometry enables the identification of binding partners and interactors, whether studying proteins, long non-coding RNAs, or protein complexes. Techniques such as native MS, tandem affinity purification, and proximity labeling (e.g., TurboID-based workflows) provide deeper insights into molecular networks and signaling pathways.These approaches are essential for understanding how candidate drug targets function within complex biological systems.<h5>Sample Preparation Challenges in Biological Research</h5>Sample preparation remains one of the most challenging aspects of biological experimentation. Whole-cell lysates contain proteases, nucleases, and other components that can rapidly degrade target molecules. Preventing degradation requires minimizing preparation time, maintaining low temperatures, and using appropriate inhibitor cocktails.Reproducibility is also critical: biological experiments require multiple replicates, and variability is often unavoidable. Careful handling, protocol optimization, and continuous troubleshooting are essential to ensure reliable results, whether preparing samples for chromatography, mass spectrometry, sequencing, or immunoprecipitation.<h5>Advances in Chromatography and MS for Malaria Research</h5>Modern advances in chromatography and mass spectrometry significantly enhance malaria research by enabling precise target identification, quantification, and functional characterization. Drug discovery workflows begin with construct design and recombinant expression, followed by purification and interaction studies.In malaria research, stage-specific parasite biology requires careful extraction and analysis of proteins from different life cycle stages. Tandem affinity MS, immunoprecipitation, and in vivo validation studies help confirm target relevance and therapeutic potential.Recent work on repurposed kinase inhibitors has shown promising results, including inhibition of hemozoin formation—a key detoxification pathway for the malaria parasite—highlighting the potential of such compounds for further development.<h5>Malaria, Drug Resistance, and Global Impact</h5>Malaria remains a major global health burden, with over 600,000 deaths annually and widespread drug resistance complicating treatment. Artemisinin resistance, particularly associated with mutations in the K13 propeller domain, has driven the search for new targets and therapies.During her PhD, Subhoja focused on falcipain-2, a cysteine protease involved in hemoglobin degradation within the parasite. This pathway is critical for parasite survival and has emerged as a promising drug target. Her work revealed that falcipain-2 operates within a larger protein complex responsible for hemoglobin processing and amino acid release.Understanding these molecular mechanisms is essential for developing robust, stage-specific antimalarial strategies.<h5>Advice for Early-Career Researchers</h5>For researchers just starting out, Subhoja emphasizes the importance of hands-on experience. Working directly with cells, lysates, and analytical tools is essential for truly understanding experimental systems. Failure is an inherent part of research, and perseverance is key.Motivation, teamwork, careful sample handling, and thorough preparation all contribute to long-term success. Reading extensively, critically evaluating one’s own work, and appreciating incremental progress are vital aspects of a sustainable research career.Every successful experiment—no matter how small—represents meaningful progress and contributes to the broader goals of science and medicine.<h5>Closing Remarks</h5>The discussion highlights how interdisciplinary approaches combining chromatography, mass spectrometry, structural biology, and biochemistry are driving advances in malaria drug discovery. Through careful experimental design, analytical rigor, and collaborative teamwork, researchers can address complex biological challenges and contribute to global health solutions.<blockquote>This text has been automatically transcribed from a video presentation using AI technology. It may contain inaccuracies and is not guaranteed to be 100% correct.</blockquote><blockquote><h4>Concentrating on Chromatography Podcast</h4>Dive into the frontiers of chromatography, mass spectrometry, and sample preparation with host David Oliva. Each episode features candid conversations with leading researchers, industry innovators, and passionate scientists who are shaping the future of analytical chemistry. From decoding PFAS detection challenges to exploring the latest in AI-assisted liquid chromatography, this show uncovers practical workflows, sustainability breakthroughs, and the real-world impact of separation science. Whether you’re a chromatographer, lab professional, or researcher you'll discover inspiring content!You can find Concentrating on Chromatography Podcast in podcast apps:<ul><li><a target="_blank" rel="noopener noreferrer" href="https://open.spotify.com/show/1wZg67rCjoGju4yhqxI3tL">Spotify</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://podcasts.apple.com/tz/podcast/concentrating-on-chromatography/id1788429185">Apple podcast</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://podscan.fm/podcasts/concentrating-on-chromatography">podscan</a></li></ul>and on <a target="_blank" rel="noopener noreferrer" href="https://www.youtube.com/@ChromatographyTalk/videos">YouTube channel</a></blockquote>

Affinity, Gel Filtration, Size Exclusion Chromatography: Repurposing Kinase Inhibitors for Malaria

In the week of February 9, the following webinars await you in the field of liquid phase and especially HPLC and LC/MS.<blockquote><h4><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinars">👉 DETAILS AND REGISTRATION IN THE WEBINARS SECTION</a></h4>👉 Search and filter in the largest global database with over 5 000 GC, LC, MS and spectroscopy webinars.</blockquote><h5>1. SelectScience: High-Throughput Stability Screening Strategies for Antibody Formulation</h5><ul><li>Tu, 10.2.2026 17:00 CET</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/5807">Registration</a></li></ul>Learn how high-throughput DLS/SLS and rapid-screening DSC accelerate stability assessment of high-concentration antibody formulations, enabling faster, data-driven biologics development.<h5>2. Phenomenex: Big Scale, Big Wins – Prep Chromatography Explained</h5><ul><li>We, 11.2.2026 10:00 CET</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/5793">Registration</a></li></ul>Learn how to scale analytical methods to preparative HPLC, optimize loading capacity, and understand the limits of preparative columns for pharmaceutical applications.<h5>3. ALS Czech Republic: PFAS in Food &amp; Food Contact Material</h5><ul><li>We, 11.2.2026 15:00 CET</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/5816">Registration</a></li></ul>Get a practical overview of PFAS in food and food contact materials, including EU and US regulations, key analytical challenges, and reliable PFAS testing strategies.<h5>4. New Food Magazine: The Science of Next-Gen Ingredients – Fermentation, Formulation and Function</h5><ul><li>We, 11.2.2026 16:00 CET</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/5720">Registration</a></li></ul>Explore how fermentation-driven innovation is transforming functional food ingredients and how advanced analytics optimize flavour, functionality, and stability.<h5>5. SCIEX: Accurate Mass Fundamentals – Interpreting and Applying Your Data</h5><ul><li>We, 11.2.2026 19:00 CET</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/5772">Registration</a></li></ul>Session 3 focuses on interpreting and applying accurate mass data to confirm compound identity, move beyond basic quantitation, and troubleshoot results for confident reporting.<h5>6. Agilent Technologies: Process Analytical Techniques – Online HPLC for Real-Time Monitoring and Control of Bioprocesses</h5><ul><li>Th, 12.2.2026 06:30 CET</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/5834">Registration</a></li></ul>Discover how PAT HPLC enables near-real-time monitoring of critical quality attributes in bioprocessing, with a case study on charge-variant control by cation-exchange chromatography.<h5>7. Thermo Fisher Scientific: Introducing the Orbitrap Excedion Pro Hybrid MS</h5><ul><li>Th, 12.2.2026 11:00 CET</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/5889">Registration</a></li></ul>Discover the new Orbitrap Exploris Pro with expanded ETD/EThcD capabilities for confident biopharmaceutical characterization, including intact proteins, PTMs, ADCs, and large biomolecules.<h5>8. Waters Corporation: Planning Your NuGenesis Upgrade – Insights and Best Practices for a Smooth Transition</h5><ul><li>Th, 12.2.2026 19:00 CET</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/5833">Registration</a></li></ul>Learn how to plan a successful NuGenesis upgrade, transition to Windows 11, and unlock new capabilities such as dashboards for real-time operational insights.<h5>9. Thermo Fisher Scientific: Comprehensive Analytical Strategies for Peptide Therapeutics and GLP-1 Agonists with Agilent</h5><ul><li>Th, 12.2.2026 19:00 CET</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/5814">Registration</a></li></ul>Explore analytical workflows for peptide therapeutics, including method development, peptide mapping, GLP-1 QC, and LC-MS strategies across Agilent platforms.<h5>10. Agilent Technologies: Moving from R&amp;D and Limited QC on a UV-Vis-NIR Instrument to Large-Scale QC Using an Autosampler</h5><ul><li>Th, 12.2.2026 20:00 CET</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/2104">Registration</a></li></ul>This webinar covers practical aspects of adding and using an autosampler to maximize UV-Vis-NIR QC workflows at scale.<h5>11. Agilent Technologies: LC Method Transfer – Hidden Challenges &amp; Absolute Solution</h5><ul><li>Fr, 13.2.2026 06:30 CET</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/5787">Registration</a></li></ul>Discover why LC method transfer between legacy and modern systems is challenging, which hidden parameters affect retention and peak shape, and how to achieve robust, reliable results.

Webinars LabRulezLCMS Week 07/2026

Charge detection mass spectrometry (CDMS) allows direct mass determination of individual ions and is increasingly used to study heterogeneous biological samples. This work demonstrates the use of Orbitrap-based CDMS/Direct Mass Technology (DMT) for quantitative analysis of transthyretin (TTR) tetramer samples below 100 kDa, extending CDMS beyond its traditional qualitative role.DMT resolved wild-type and C-terminally modified TTR homotetramers, as well as hybrid tetramers, enabling kinetic analysis of subunit exchange and stability. The approach also quantified thyroxine binding to TTR variants, revealing differences in binding affinity linked to C-terminal modification. By separating overlapping m/z signals through charge measurement, CDMS enables accurate mass and abundance determination, highlighting its potential for quantitative analysis of complex protein systems.<blockquote><h4>The original article</h4><h4><a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acs.analchem.5c05771">Dissecting Heterogeneous Populations of Protein-Complex Samples Using Direct Mass Technology</a></h4>Robert L. Rider, Jared Hampton, Zhenyu Xi, Carter Lantz, Sangho D. Yun, Weijing Liu, Rosa Viner, Arthur Laganowsky, and David H. Russell*Anal. Chem. 2025, 97, 49, 27057–27063<a target="_blank" rel="noopener noreferrer" href="https://doi.org/10.1021/acs.analchem.5c05771">https://doi.org/10.1021/acs.analchem.5c05771</a><h6>licensed under <a target="_blank" rel="noopener noreferrer" href="https://creativecommons.org/licenses/by/4.0/">CC-BY 4.0</a></h6></blockquote>Selected sections from the article follow. Formats and hyperlinks were adapted from the original.Transthyretin (TTR) is a homotetrameric transport protein that circulates in plasma and cerebrospinal fluid, delivering thyroxine (T4) and retinol-binding protein–vitamin A complexes. <a href="javascript:void(0);">(1)</a> The stability of the TTR tetramer is central to its physiological role because dissociation into monomers can initiate misfolding and amyloid formation, leading to systemic or hereditary transthyretin amyloidosis. <a href="javascript:void(0);">(2)</a> Subunit exchange between wild-type (WT) and variant TTR proteoforms, including disease-associated mutations such as V30M and V122I, have been implicated in amyloid progression by generating hybrid tetramers (tetramers containing WT and mutant subunits) with altered stabilities. <a href="javascript:void(0);">(3,4)</a> Ligand binding, particularly at the two thyroxine-binding sites located at the dimer–dimer interface, can kinetically stabilize the tetramer and modulate amyloidogenicity. <a href="javascript:void(0);">(5,6)</a> Accurate measurement of both subunit exchange kinetics and ligand binding stoichiometry is therefore critical for elucidating the TTR dynamics and stability.Affinity or sequence tags are widely employed in protein expression, purification, or detection. <a href="javascript:void(0);">(7,8)</a> While these tags are often assumed to be inert, their influence on protein structure and dynamics are rarely examined in detail. <a href="javascript:void(0);">(9,10)</a> Protein tags at the N- and C-terminus of TTR have been shown to have differing gas phase stabilities from those of WT-TTR. <a href="javascript:void(0);">(11)</a> The C-terminus is of particular interest because this region participates in the dimer–dimer interface that governs tetramer stability. <a href="javascript:void(0);">(11,12)</a> Characterizing how the C-terminal tag (CT) (-ASGENLFYQ) affects TTR’s solution stability and ligand binding is not only relevant for understanding TTR dynamics but also provides an example of how expression tags can alter protein dynamics. <a href="javascript:void(0);">(13)</a>Native mass spectrometry (nMS) has been invaluable for characterizing protein complexes, <a href="javascript:void(0);">(14)</a> yet conventional nMS often struggles with heterogeneous samples where overlapping charge state distributions and adduct heterogeneity limit resolution and quantitation. <a href="javascript:void(0);">(15)</a> Charge detection mass spectrometry (CDMS) addresses these limitations by independently measuring the charge and m/z of individual ions, enabling the direct determination of molecular mass and abundance. Development of CDMS has largely focused on achieving higher mass resolution <a href="javascript:void(0);">(16)</a> and extending measurements toward assemblies into the GDa range. <a href="javascript:void(0);">(17,18)</a> However, there is untapped utility for CDMS experiments other than mass and proteoform determination. Jordan et al. showed the capability to assess conformational heterogeneity of mAb aggregates using the added charge dimension that CDMS provides. <a href="javascript:void(0);">(19)</a> The current work demonstrates that CDMS can separate proteoforms with overlapping m/z values based on charge and quantify their relative abundances in complex mixtures. While nMS is already a highly quantitative technique, our results establish CDMS as an equally powerful tool for quantitative analysis in heterogeneous systems. <a href="javascript:void(0);">(20,21)</a>Here, we apply Orbitrap-based CDMS/Direct Mass Technology (DMT) using the selective temporal overview of resonant ions (STORI) approach <a href="javascript:void(0);">(22,23)</a> to quantitatively compare WT-TTR and CT-TTR, focusing on two biologically relevant properties: tetramer stability assessed via subunit exchange kinetics and ligand-binding affinity. Conventional nMS cannot fully resolve the overlapping charge states of WT- and CT-TTR or their ligand-bound states. However, DMT can resolve these species by directly measuring the mass (m/z × charge), enabling quantitation of all proteoforms. The data reveal that the CT tag alters tetramer stability and thyroxine-binding affinity, demonstrating the structural sensitivity of TTR to modifications at its C-terminus. More broadly, this work demonstrates the impact that protein tags can have on native protein interactions and highlights the broader utility of quantitative CDMS for probing heterogeneous biological samples.<h4>Experimental Section</h4><h5>Data Collection</h5>All experiments were conducted on a <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/560">Thermo Scientific Q-Exactive UHMR</a> with added DMT capabilities (Bremen, Germany). Before DMT, mass spectra were collected at various resolving powers (6–200k) for each sample, with the instrument parameters reported in the Supporting Information (<a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/suppl/10.1021/acs.analchem.5c05771/suppl_file/ac5c05771_si_001.pdf">Table S1</a>). For DMT experiments, the trapping gas pressure in the HCD cell was reduced to 0.3–0.8 to attenuate the signal intensity to a single ion level, as well as decreasing the UHV pressure to assist ion retention through the entire transient of Orbitrap analysis. We observed no significant difference between mass spectra collected at various HCD cell pressures (Supporting Information, <a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/suppl/10.1021/acs.analchem.5c05771/suppl_file/ac5c05771_si_001.pdf">Figure S1</a>). For DMT collection, automated ion control (AIC) and 100% target density were used with 200k resolving power.<h4>Results and Discussion</h4>CDMS has emerged as a powerful tool for analyzing heterogeneous biomolecular samples, enabling accurate, direct mass determination by simultaneously measuring the charge and m/z for individual ions. While CDMS has been widely applied for qualitative analyses, its potential for quantitative and less than MDa applications remains underexplored. <a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acs.analchem.5c05771#fig1">Figure 1</a>A shows the theoretical mass spectrum of WT-TTR (14+ to 16+) and CT-TTR (15+ to 17+) homotetramers, where the two proteoforms become increasingly resolved as the charge states increase (&lt;3900 m/z). <a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acs.analchem.5c05771#fig1">Figure 1</a>B zooms in on the 14+ (WT) and 15+ (CT) charge states, highlighting their strong overlap, which prevents accurate deconvolution of the proteoforms by conventional methods. <a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acs.analchem.5c05771#fig1">Figure 1</a>C displays theoretical distributions for 0, 1, and 2 T4 bound states of both WT- and CT-TTR tetramers, where &lt;3900 m/z has observable separation between all proteoforms. However, for the 14+ and 15+ charge states of WT- and CT-TTR, respectively, the 0 T4- and 1 T4-bound populations overlap (<a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acs.analchem.5c05771#fig1">Figure 1</a>D). Furthermore, commonly adducted species (Na+, K+, and Zn2+) observed in experimental spectra broaden these distributions, making it increasingly difficult to distinguish and deconvolute the proteoforms (see <a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/suppl/10.1021/acs.analchem.5c05771/suppl_file/ac5c05771_si_001.pdf">Figure S2</a>). Here, we employ Orbitrap-based CDMS/DMT to overcome this m/z overlap to resolve and quantify hybrid tetramer formation and T4 binding.<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Anal_Chem_2025_97_49_27057_27063_Figure_1_A_Theoretical_mass_spectra_of_WT_TTR_and_CT_TTR_homotetramers_47232849d9.jpg" alt="Anal. Chem. 2025, 97, 49, 27057–27063: Figure 1. (A) Theoretical mass spectra of WT-TTR and CT-TTR homotetramers. (B) Zoomed-in view of the 14+ WT-TTR and 15+ CT-TTR distributions to show the large overlap of the proteoforms. (C) Theoretical mass spectra of WT-TTR and CT-TTR homotetramers with thyroxine (T4) binding. (D) Zoomed-in view of the 14+ WT-TTR and 15+ CT-TTR distributions where the 0 and 1 T4 have overlapping distributions. These theoretical distributions do not contain any commonly adducted species (Na+, K+, Zn2+), which broaden the distributions and create more overlap even for the proteoforms in the range 3300–3900 m/z (see Figure S2)." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Anal_Chem_2025_97_49_27057_27063_Figure_1_A_Theoretical_mass_spectra_of_WT_TTR_and_CT_TTR_homotetramers_47232849d9.jpg 187w," sizes="100vw" width="1417" height="1182"><h5>Thyroxine Binding to TTR Homotetramers</h5>Thyroxine is the less active form of a thyroid hormone important for metabolism that binds to TTR for transport throughout plasma and cerebral spinal fluid. <a href="javascript:void(0);">(31)</a> Turnover of T4 into T3 (active) occurs after dissociation, where it can then modulate gene expression via binding to nuclear receptors. <a href="javascript:void(0);">(32)</a> The TTR tetramer gains substantial stability as it binds up to 2 T4 at the tetramer interface, decreasing tetramer dissociation and SUE. <a href="javascript:void(0);">(33)</a> This has been shown previously to decrease the amyloidogenic rate of TTR, which led to tafamidis (similar in structure to T4) to be designed and is currently the only drug that is approved for clinical treatment of TTR amyloidosis. <a href="javascript:void(0);">(34)</a> Measuring the difference in binding affinity between TTR proteoforms may provide insight into regions of TTR or TTR intermolecular/intramolecular interactions that are important for binding of small molecules such as tafamidis and T4.DMT was further applied to quantify T4 binding to WT- and CT-TTR homotetramers, highlighting the technique’s utility in probing protein–ligand interactions. <a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acs.analchem.5c05771#fig3">Figure 3</a>A shows a representative mass spectrum of TTR homotetramers in the presence of T4. While ligand-bound species can be observed, homotetramers cannot be confidently resolved across the entire 3000–5000 m/z range. By leveraging the charge-resolving capabilities of DMT, we achieve separation of the homotetramers (<a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acs.analchem.5c05771#fig3">Figure 3</a>B,C) and the 0, 1, and 2 ligand-bound states. The 2D plot clearly shows the gain in resolution achieved when charge is simultaneously measured with m/z by separating the 14+ and 15+ charge states for WT and CT, respectively, in the range 3900–4200 m/z. Additionally, using ion mobility does not provide the same kind of 2D resolution due to the similarity in arrival times for the homotetramer proteoforms, as evidenced by <a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/suppl/10.1021/acs.analchem.5c05771/suppl_file/ac5c05771_si_001.pdf">Figures S4 and S5</a> (see the Supporting Information). These data provide evidence that when ion mobility is able to separate out species that overlap in m/z yet differ in mobility, CDMS could be an alternative or used complementarily since the species likely also differ in charge.<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Anal_Chem_2025_97_49_27057_27063_Figure_3_A_Mass_spectra_of_WT_TTR_and_CT_TTR_homotetramers_with_thyroxine_binding_61b1e98a94.jpg" alt="Anal. Chem. 2025, 97, 49, 27057–27063: Figure 3. (A) Mass spectra of WT-TTR and CT-TTR homotetramers with thyroxine binding. Ligand binding can be resolved, but homotetramers cannot be confidently identified. Charge states labeled are for WT; CT is always one charge state higher at the same m/z range. (B) DMT heatmap resolving WT-TTR and CT-TTR homotetramers with the additional measurement of charge. (C) Deconvoluted mass spectrum from DMT analysis. Both homotetramers and their ligand binding are resolved, and fit for analysis is shown in red. (D) Mole fraction of each homotetramer and their thyroxine binding species. Error bars represent the standard deviation of replicates (n = 3). The significance for each ligand state is in respect to the left adjacent state. *p &lt; 0.05." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Anal_Chem_2025_97_49_27057_27063_Figure_3_A_Mass_spectra_of_WT_TTR_and_CT_TTR_homotetramers_with_thyroxine_binding_61b1e98a94.jpg 181w," sizes="100vw" width="1266" height="1094"><h4>Conclusion</h4>This work demonstrates that quantitatively, Orbitrap-based CDMS/DMT can determine differences in protein-complex stability and ligand binding. By directly comparing WT- with CT-TTR, we show that the CT tag accelerates tetramer dissociation while enhancing T4 binding affinity. These results indicate that the C-terminus, located at the dimer–dimer interface, plays a more significant role in TTR stability and ligand recognition than previously appreciated. <a href="javascript:void(0);">(12)</a> Even the addition of a short peptide sequence perturbs noncovalent interactions at the interface, likely altering solvent accessibility, and the dynamics of the thyroxine binding channel. <a href="javascript:void(0);">(37,54)</a> Such findings underscore the importance of evaluating how seemingly minor sequence modifications, such as affinity tags, can influence fundamental biophysical properties.Beyond TTR, this work positions quantitative CDMS as a broadly applicable strategy for analyzing heterogeneous protein systems, where charge domain separation overcomes the resolution limits of m/z domain measurements in traditional nMS experiments. While much of the field has emphasized extending CDMS to ultrahigh masses and maximal resolution, <a href="javascript:void(0);">(16,18)</a> our results highlight the underexplored potential of applying the method in the 1000–10,000 m/z range common to nMS experiments. This capability is directly relevant to heterogeneous membrane protein complexes, which often display broad distributions of oligomeric states, PTMs, lipid, and ligand adducts that complicate spectra. <a href="javascript:void(0);">(48,55)</a> Similarly, mAbs can oligomerize and exhibit mass heterogeneity from variable glycosylation, affecting pharmacokinetics, effector function, and stability. <a href="javascript:void(0);">(19)</a> CDMS may resolve and quantify such proteoforms in a single experiment without the need for charge reduction or chemical derivatization. <a href="javascript:void(0);">(48,56,57)</a>

Dissecting Heterogeneous Populations of Protein-Complex Samples Using Direct Mass Technology

Article

Webinars

Video

Scientists

Scientific article

Interview

Science and research

Everything from the world of analytical chemistry in one place. We connect people in solving their problems. At Labrulez you will find all the necessary information easily, quickly and clearly. Stop searching and start finding.

LabRulez

Organomation, founded in 1959, designs and manufactures high-quality nitrogen evaporators and extraction systems. Known for innovation and durability, their lab instruments are used globally for efficient sample preparation with strong customer support.

Organomation

Tosoh Bioscience

Phenomenex

Thermo Fisher Scientific

SelectScience

VWR/Avantor

Waters Corporation

PhenoAcademy Webinars
 Liquid Chromatography Series
<h4>A Guide to Building Your LC Method Development Kit Plus Tips on Storage &amp; Care</h4>
<ul>
<li>Learn how to choose different column phases for developing a LC method</li>
<li>Understand what kind of LC columns can be a strong method development kit</li>
<li>Identify how to take care of your LC column to extend its lifetime</li>
</ul>
<blockquote>
Presenter: Kevin Zhao (Senior Technical Specialist)
</blockquote>
<blockquote>
Kevin Zhao is the Senior Technical Specialist with Phenomenex and has 5 years of experience in biochemistry research; 4 years of Protein/Cancer research with CSULA-City of Hope Cancer Collaborative and over 9 years in Phenomenex. Mr. Zhao is a member of a global Technical Support Team which includes providing problem-solving, troubleshooting, and applications assistance for customers worldwide in the fields of chromatography (liquid and gas) and sample preparation, and also handling Industries supported include – pharmaceutical and biopharmaceutical, clinical research and clinical toxicology, food safety, environmental, fuels and specialty chemicals. Mr. Zhao received his B.S. in Biology at the California State Polytechnic University, Pomona. earned his M.S. in Biochemistry at California State University, Los Angeles, and also earned a MBA at the University of the Incarnate Word.
</blockquote>
<blockquote>
Presenter: Koen Askamp (Technical Specialist)
</blockquote>
<blockquote>
Koen is from the Netherlands, studied Molecular Life Sciences at Wageningen University (Netherlands), majoring in immunology. Analytical Chemistry was one of my favorite courses – who doesn’t love solving puzzles?
</blockquote>
<blockquote>
I like drumming, scuba diving, motorcycle-riding, and this past winter I learned how to ski (a little)!
</blockquote>
<blockquote>
Presenter: Namrata Saxena (Technical Manager)
</blockquote>
<blockquote>
Namrata Saxena is a Technical Manager - Asia/Pacific” with Phenomenex and is based in Sydney, Australia. She has a post graduate degree with a specialization in Analytical Chemistry, with extensive experience in the Liquid chromatography domain, and her current focus is in Omics and Biologics field. 
</blockquote>
<blockquote>
Before joining Phenomenex she had worked as “Product Specialist” and spent several years in column chemistry, column manufacturing and method development in the application and manufacturing labs of Bischoff Chromatography, Germany. 
</blockquote>
<blockquote>
In her current role, she provides product selection, method development, training and troubleshooting support to customers as well as Phenomenex Sales Consultants globally. 
</blockquote>

Phenomenex: PhenoAcademy Webinars - Liquid Chromatography Series

A Guide to Building Your LC Method Development Kit Plus Tips on Storage & Care

Learn how to choose different column phases for developing a LC method.

Building LC Method Development Plus Tips on Storage & Care

Aggregate analysis of Adeno Associated Virus (AAV) is crucial for quality assessment and currently presents various challenges including long run time, high volume sample consumption where samples are scares and over all requires reliable technique to address all aspects related to quality and throughput.
In this webinar, the speakers will focus on optimizing a high throughput SEC method using a novel size exclusion chemistry to reduce sample consumption and run time. Additionally, method versatility with multiple mobile phase, multiple detectors across various AAV serotypes will be explored. 
<h5>Key Learning Points:</h5>
<ul>
<li>Learn about a novel Size exclusion chemistry that can improve lab throughput and reduce sample consumption for AAV analysis</li>
<li>Find new method optimization tips and tricks to maximize AAV Aggregate separation</li>
<li>Understand how optimizing particle chemistry, pore size and hardware can improve Aggregate separation in Size Exclusion Chromatography of AAVs</li>
</ul>
<blockquote>
Presenter: Shilin Cheung, PhD (Sr. Research Scientist, Phenomenex)
</blockquote>
<blockquote>
Dr. Cheung received her BS (2006) and Ph.D. (2012) in Bioanalytical Chemistry from the University of Toronto. She has developed, qualified, and validated innovative analytical methods in CE based microfluidics, automated low volume UV-vis spec., and UHPLC assays. Her methods have been applied to manufacturing process developments, formulation and stability and DS/DP characterization and specification testing. At the Phenomenex Innovation Campus she is focused on developing fit for purpose analytical methods to help advance developments in gene therapeutics.
</blockquote>
<blockquote>
Presenter: Ramkumar Dhandapani, PhD (Senior Product Manager, Phenomenex)
</blockquote>
<blockquote>
Dr. Dhandapani has been in the chromatography industry for over 20 years with hands-on and troubleshooting experience. He has earnt a Masters and PhD degree in Analytical chemistry from Seton Hall University with specialization in Microextractions, Multidimentional Chromatography and Tandem Mass Specs techniques. He has developed and validated several regulatory compliant methods in Pharmaceutical, Food, Fuels and Environmental industry as well as incorporated method improvement and troubleshooting across a range of separation techniques. Dr. Dhandapani joined Phenomenex in August of 2014 and he serves as a Senior Product Manager at Phenomenex. In addition to managing the product line, Dr. Dhandapani presents on innovations in chromatography at various chromatography conference.
</blockquote>

Phenomenex: Overcoming Challenges with AAV Aggregate Analysis Using a Novel Size Exclusion Particle

Overcoming Challenges with AAV Aggregate Analysis Using a Novel Size Exclusion Particle

Optimization of high throughput SEC method using a novel size exclusion chemistry to reduce sample consumption and  run time

AAV Aggregate Analysis Using a Novel Size Exclusion Particle

HPLC and LC-MS method development can be challenging, especially for complex samples. Whether the complexity comes from the sample itself, or the sample matrix, there are different approaches that can be taken to help resolve more peaks in these types of sample.
<h4>1. A practical guide to maximize the sample peak capacity for complex small molecule separations</h4>
<ul>
<li>Dr. Arianne Soliven – Product Specialist, Avantor, UK</li>
</ul>
Method development for complex small molecule samples using reversed-phase (RP) separation conditions is a challenging problem, especially when the sample matrix itself may contain many unknown analytes in a dynamic range of different concentrations. This talk is based on guiding analysts on an established approach published in 2013 aimed at optimizing the practical method decisions: (column length (L), temperature (T), flow rate (F), and final organic strength mobile phase composition (∅final) to maximize the separation’s peak capacity.
<h4>2. Software-assisted method development enables the optimization of chromatographic separation and enhancement of peak capacity</h4>
<ul>
<li>Dr. Imad Haidar Ahmad - Research Director, Amgen, USA</li>
</ul>
Software-assisted method development is a powerful tool to achieve optimal performance in chromatographic separations. In the pharmaceutical industry, chromatographic modelling is a fundamental part of the analytical workflow, which focuses on chromatography column selection along with optimizing mobile phase composition and gradient conditions. This integration of chromatography modelling into analytical workflow enables accelerating method development and ensures compliance to regulatory requirements. In this presentation, we show how chromatography modelling can be used to pick the optimum selectivity, shorten cycle time, decrease peak width, and enhance resolution, which is translated into higher peak capacity. We will highlight the use of modelling to increase peak capacity and address challenging separations by showcasing several real-life methods employed in the pharmaceutical industry.
<h4>3. Strategies for trace contaminant analysis in complex sample matrices</h4>
<ul>
<li>Dr. Andrés Pérez-Parada - Professor at the University of the Republic, Uruguay</li>
</ul>
Various types of organic pollutants can be present in both food and environmental samples. This presentation aims to showcase the practical applications of LC-FLD in the routine analysis of glyphosate in freshwater and agricultural soils. Additionally, rapid determination of Ochratoxin A in wines will be demonstrated, employing advanced core-shell Avantor LC columns. Furthermore, the presentation will delve into the environmental dissipation of rice pesticides, presenting large-scale multi-residue methods using LC-MS/MS. This overview will give insights into the analytical versatility and efficacy of LC in addressing diverse challenges related to organic pollutant analysis.

Avantor: Different Perspectives and Strategies for Liquid Chromatography Peak Capacity Optimization and Method Development

Different Perspectives and Strategies for Liquid Chromatography Peak Capacity Optimization and Method Development

LC Peak Capacity Optimization and Method Development

Size exclusion chromatography (SEC) is a commonly used technique throughout the research, development, and commercialization of biotherapeutic proteins and peptides.
The key to successful SEC methods begins with selecting an appropriate SEC column, based on application need and LC instrumentation, and separation method to generate reliable quantitative data.
This webinar will provide an overview on how to select an appropriate SEC column for your application and separation challenges. It will also review how to maximize SEC column life, ways to address concerns if, and when, they arise, and technology that reduces non-desired protein to SEC particle / column secondary interactions.
<h5>Topics:</h5>
<ul>
<li>Four steps in determining an appropriate SEC column based on application and LC instrumentation</li>
<li>SEC method development</li>
<li>Overcoming non-desired protein and column secondary interactions</li>
<li>Is a platform SEC method possible?</li>
<li>Considerations to maximize SEC column life</li>
</ul>
<blockquote>
Presenter: Mary Trudeau (Consulting Scientist and Manager of the Sample Prep and Automation group, Waters Corporation)
</blockquote>
<blockquote>
Mary Trudeau is a Consulting Scientist and manager for the Sample Preparation group within the Consumable and Lab Automation Division. Following a successful career in pharma with Pfizer, Mary joined Waters in 2011. She is responsible for developing and optimizing methods and workflows to address customer pain points across multiple market segments. Her team’s primary focus has been developing and highlighting automated sample preparation bioanalytical ADME/DMPK workflows for both small and large molecules.
</blockquote>
<blockquote>
Presenter: Bill Warren (Principal Consultant Product Manager, Waters Corporation)
</blockquote>
<blockquote>
In 1986, Bill joined Waters Corporation as a senior applications chemist involved with the research and development of HPLC, FPLC, and Capillary Electrophoresis applications for the analysis and purification of proteins, peptides, and nucleic acids. He currently is a Principal Consulting Bio separations Product Manager whose responsibilities involve assisting in the development and commercialization of innovative reagents and chromatography-based technologies for the separation, purification, and characterization of proteins and peptides.
</blockquote>
<blockquote>
Presenter: Stephan M. Koza, Ph.D. (Consulting Scientist, Waters Corporation)
</blockquote>
<blockquote>
Stephan has worked at Waters Corporation for over 10 years and has a primary focus on the use of LC, LC-MS, and sample preparation chemistries and columns for the analysis of biomolecules. Prior to joining Waters, he had nearly twenty years of experience with biopharmaceutical characterization and analytical method development with Genetics Institute, Wyeth, and Pfizer. Stephan received his doctorate in analytical chemistry at the University of New Hampshire.
</blockquote>
<blockquote>
Presenter: Leslie Napoletano (Principal Product Marketing Manager, Waters Corporation)
</blockquote>
<blockquote>
Leslie has been with Waters since 2012 providing support and education to scientists in New Jersey with Waters chemistry consumables including sample preparation, column selection and delivering educational seminars to customers. More recently in 2021, Leslie has moved into the Product Marketing group focusing on bringing on new consumable products for protein characterization. Prior to joining Waters, Leslie worked as a scientist in protein characterization in the pre-clinical development of monoclonal antibodies at Merck and prior to that at Teva as a R&amp;D chemist.
</blockquote>

Waters Corporation: SEC Column Selection and Care for Biotherapeutic Proteins & Peptides

SEC Column Selection and Care for Biotherapeutic Proteins & Peptides

This webinar will provide an overview on how to select an appropriate SEC column for your application and separation challenges.

SEC Column Selection and Care for Biotherapeutics

In this live webinar, we will introduce the brand new Thermo Scientific™ Hypersil GOLD™ Peptide LC Column, designed for all peptide separation, including excellent retention of hydrophilic peptides and separation of deamidated species in a single run. This column is ideal for the development and manufacturing of biopharmaceuticals, achieving minimal RSD% and impeccable lot-to-lot consistency.
Following a product presentation of this advanced technology, you will get a chance to hear testimonies and results from our customers and early-adopters in the field. Finally, our experts will proceed to dive deeper into the related applications, such as peptide mapping and monitoring as part of the Multi-Attribute Method (MAM), to provide you with the solutions to resolve all your peptide challenges. We hope to see you there! 
Learning Points:
<ul>
<li>Introduction to the new Hypersil GOLD Peptide LC Column</li>
<li>Hear from early adopters about their use of this advanced technology</li>
<li>Dive deeper into the related applications to resolve all peptide challenges</li>
</ul>
Who should attend?
<ul>
<li>Biopharmaceutical research scientists</li>
<li>Analytical scientists from biopharma companies working on or interested in peptide mapping and monitoring</li>
<li>PhD students and scientists looking to advance their knowledge of peptide mapping and monitoring</li>
</ul>
Short notice:
Can&#39;t attend the live broadcast? No problem! Register anyway and you will automatically receive the link to the webinar recording. 
<blockquote>
Presenter: Serdar Bilgesoy (Product Manager Premier LC columns, Thermo Fisher Scientific)
</blockquote>
<blockquote>
As the Global Product Manager for LC Columns at Thermo Fisher Scientific, Serdar brings over 15 years of experience in analytical instruments across various roles in product management, sales, marketing, application, and service responsibilities. He has specialized in segments such as Life Sciences, Clinical, Pharma, Biopharma, and Forensics. He is an experienced Application, Sales, and Marketing Executive in HPLC, LC-MS/MS, LC-MS/TOF, and MALDI-TOF instruments, possessing sophisticated marketing knowledge, a vast sales network, technical background, and innovative solutions expertise.
</blockquote>

ThermoFisher Scientific: Resolve all your peptide challenges: deep dive into new separation technology and applications

Resolve all your peptide challenges: deep dive into new separation technology and applications

We will introduce the brand new Thermo Scientific™ Hypersil GOLD™ Peptide LC Column, designed for all peptide separation.

Peptide challenges: new separation technology

By attending this eSeminar, you will:
<ul>
<li>Gain practical insights into optimizing sample preparation in alignment with EPA Method 1633’s regulatory requirements by the use of dual-phase SPE cartridges, covering background analysis, MDL studies, and recoveries</li>
<li>Benefit from real-world experiences from Complete Environmental Testing, offering valuable insights on navigating EPA 1633 in an end-to-end workflow, while utilizing dual-phase SPE cartridges to improve laboratory efficiency</li>
<li>Understand key details for successful PFAS analysis</li>
<li>Learn how to optimize analysis for ultra-short chain PFAS compounds</li>
<li>See how to expand the range of PFAS compounds to analyze in a single run</li>
</ul>
<h4>Event Overview</h4>
Separation Science, in collaboration with its sponsors Waters and Restek, is pleased to bring you an upcoming online eSeminar focusing on advances in PFAS analysis. This unique event will bring together key experts in the field and provide an interactive learning environment for scientists working in this industry.
<h4>Presentations</h4>
Efficiency in EPA Method 1633: Validation and Implementation Strategies
by Jeffrey Smith, Director of Operations, Complete Environmental Testing (CET)
Join us for a presentation focused on optimizing EPA Method 1633 in your laboratory highlighting the validation and implementation of dual-phase WAX and GCB cartridges. EPA 1633 establishes a method for the determination of 40 PFAS from challenging matrices such as non-potable waters, soils, biosolids, and tissue. For these matrix types, sample preparation has moved beyond the use of a WAX cartridge alone. GCB has been added to the sample preparation workflow to provide additional sample cleanup. We will discuss the full EPA 1633 workflow, including topics such as background analysis for soils and water, MDLs achieved, observed recovery in authentic samples, and the practical advantages of dual-phase cartridges in reducing manual labor steps compared to loose GCB in EPA 1633.
This presentation is designed for scientists, laboratory managers, and others looking to implement and validate EPA Method 1633 or optimize their sample preparation process in their current workflow. Join us as Complete Environmental Testing shares experiences on working with the complex matrices in EPA 1633 and breaks down advantages in their method workflow with the use of dual-phase SPE cartridges.
Untapped Ultrashort-chain PFAS Analysis Combined with Routine PFAS Analysis in a Single LC-MS/MS Run
by Mike Chang, Market Development Manager, Restek Corporation
Starting from measuring C8 many decades ago, today’s PFAS testing requires a lot more chromatography capabilities when an extended list of PFAS analysis is desired. Chain length ranging from C1 to C18 and a functional group changing from carboxylic acids to ethers, sulfonamides, and more, with multiple oxygens in the structure, can be challenging for a chromatograph all in one run. In this presentation, we will see examples of a combined PFAS panel analyzed in one run with chain length from C1 and above, in addition to AFFF and FTS compounds.
<h4>What you need to know:</h4>
Date: 16 April, 2024
Start times:
<ul>
<li>Broadcast 1: 9 am BST (London) / 10 am CEST (Paris/Berlin) / 1:30 pm IST (New Delhi) / 4 pm SGT (Singapore)
</li>
<li>Broadcast 2: 10 am PDT (Los Angeles) / 12 pm CDT (Chicago) / 1 pm EDT (New York)
</li>
</ul>
Duration: Approximately 90 minutes
<blockquote>
Presenter: Jeffrey Smith (Director of Operations, Complete Environmental Testing (CET))
</blockquote>
<blockquote>
Jeffrey Smith holds a BS in Chemistry from Quinnipiac University. He has been working in environmental analytical chemistry for 18 years, with experience in several disciplines, including GC/MS and LC-MS/MS. Jeffrey now serves as the director of operations at Complete Environmental Testing. For the past few years, his focus as director has been building the PFAS department at CET from the ground up, including method development and researching LC/MS/MS instrumentation for the laboratory. Jeffrey serves on several PFAS work groups and is an active member of the Reasonable Confidence QA/QC Protocols work group for the state of Connecticut.
</blockquote>
<blockquote>
Presenter: Mike Chang (Market Development Manager, Restek Corporation)
</blockquote>
<blockquote>
With an analytical chemistry background and 15+ years of experience in the chromatography industry, from instrumentation to applications, Mike is the key liaison to testing agencies and industries, bringing better ways of measuring contaminants in the environment and food. He has been chairing PFAS sessions and presenting PFAS topics at various conferences.
</blockquote>

Advances in PFAS Analysis

Understand essential details for successful PFAS analysis and optimize EPA Method 1633 in your lab.

Christian Rohrer, Director Sales and Marketing at Tosoh Bioscience GmbH, will present the next edition of Tosoh Tuesday, a webinar series held by Chromatography Experts.
On Tuesday, April 16, Corey Meadows, Product Specialist Bioanalysis at Tosoh Bioscience, dives into the analysis of antibody-drug conjugates and their drug-antibody ratio by hydrophobic interaction chromatography.
Antibody-drug conjugates (ADCs) are dual-action cancer biotherapeutics, where monoclonal antibodies carrying tumor-killing payloads specifically bind to cancer cells and accelerate cancer cell death. Characterizing the ratio of tumor-killing payload to cancer-binding antibody (DAR) is a critical quality attribute needed to determine the potential potency of a given ADC candidate. This webinar features HIC as a solution for quantifying DARs in ADC biotherapeutics. An overview of ADC and HIC fundamentals will be presented, targeting analytical method development scientists seeking insights for mobile-phase and stationary-phase selections for separating variable conjugated ADC variants.
After the webinar, ask your questions during the live Q&amp;A session. 
<blockquote>
Presenter: Christian Rohrer (Director Sales and Marketing at Tosoh Bioscience GmbH)
</blockquote>
<blockquote>
Presenter: Corey Meadows (Product Specialist Bioanalysis at Tosoh Bioscience)
</blockquote>

Tosoh Bioscience: Tosoh Tuesday - Hydrophobic Interaction Chromatography as a Platform for Characterizing ADCs

Hydrophobic Interaction Chromatography as a Platform for Characterizing ADCs

Hydrophobic Interaction Chromatography as a Platform for Characterizing Antbody-Drug Conjugates

HIC for Characterizing ADCs

<h4>European Free Educational Webinar Series</h4>
Let&#39;s go back to the basics of Chromatography, Mass Spectrometry, Data Analysis and Trouble-shooting: understanding the importance of the basics will enable you to be more effective in your daily laboratory life.
<h4>EPISODE 1</h4>
Sample Preparation - Theory and Overview
What will you learn?
<ul>
<li>Goals and available Techniques</li>
<li>Intro to Solid Phase Extraction (SPE)</li>
</ul>
<h4>What&#39;s next?</h4>
Full Webinar Series Episodes List is available <a href="https://event.on24.com/wcc/r/4551012/F69479929A905500D8B21508527807E5/5385652">here</a>
Back to Basics - Sample Preparation: Theory and Overview
<ul>
<li>Tuesday, May 07, 2024, 11:00 AM CEST</li>
</ul>
Back to Basics - Sample Preparation: Tips &amp; Tricks to make it simple
<ul>
<li>Wednesday, June 05, 2024, 11:00 AM CEST</li>
</ul>
Back to Basics - Theory of Liquid Chromatography
<ul>
<li>Wednesday, July 03, 2024, 11:00 AM CEST</li>
</ul>
Back to Basics - Basics of Liquid Chromatography
<ul>
<li>Tuesday, September 10, 2024, 11:00 AM CEST</li>
</ul>
Back to Basics - Analytical Method Development
<ul>
<li>Wednesday, October 02, 2024, 11:00 AM CEST</li>
</ul>
Back to Basics - The importance of Compliance
<ul>
<li>Tuesday, October 22, 2024, 11:00 AM CEST</li>
</ul>
Back to Basics - Introduction to Mass Spectrometry
<ul>
<li>Wednesday, November 13, 2024, 11:00 AM CET</li>
</ul>
Back to Basics - Troubleshooting your LC and MS Systems
<ul>
<li>Tuesday, December 10, 2024, 11:00 AM CET</li>
</ul>
Not sure to be able to attend live sessions?
Register today and watch the webinars on-demand
<blockquote>
Presenter: Xavier Rodriguez (Principal Sales Application Specialist, Waters)
</blockquote>

Waters Corporation: Back to Bacisc Free Educational Webinar Serries

Sample Preparation: Theory and Overview

The first episode will introduce you into goals and available techniques of Solid Phase Extraction (SPE).

<h5>Overview:</h5>
<ul>
<li>The reporting limit of a method is also dependent upon the consistency of clean blanks and elimination of sporadic contamination.</li>
<li>Vendors of PFAS consumables need to provide certified, trace level PFAS free products.</li>
<li>PFAS are everywhere! They are widely used, vendors/suppliers when contacted don&#39;t know their processes are using them.</li>
<li>Since PFAS contamination has become an issue with PFAS analysis all field samples are taken in duplicate, not just field blanks. </li>
<li>The complete data package and replicates need to be evaluated by the user in order to make sound conclusions and identify false positives. </li>
<li>Every step there is a chance to incorporate “free-range” PFAS in your sample, minimize the preparation steps</li>
<li>How PFAS is analyzed at EPA Region 5 Laboratory</li>
</ul>
<h5>Who Should Attend:</h5>
<ul>
<li>Anyone lab scientists, or managers involved in PFAS Analysis</li>
</ul>
<h5>Key Learning Points:</h5>
<ul>
<li>Learn how to approach analyzing for PFAS, it is not rocket science like they made it out to be</li>
<li>Become aware of Sporadic PFAS Contamination</li>
<li>Understand how to identify false positives</li>
<li>Require all analysis quality control and samples to be analyzed in replicates to identify false positives.</li>
</ul>
<blockquote>
Presenter: Larry Zintek (Organic Methods Group Leader, UA EPA)
</blockquote>
<blockquote>
Presenter: Maryam Sayeed (Product Management Specialist, Phenomenex)
</blockquote>

Phenomenex: Identifying and Avoid False Positives During Routine PFAS Analysis

Identifying and Avoid False Positives During Routine PFAS Analysis

Learn how to approach analyzing for PFAS, it is not rocket science like they made it out to be.

False Positives During Routine PFAS Analysis

Since 2018 when the presence of Nitrosamines was first reported in several ARB (angiotensin II receptor blocker) drugs, there has been increasing regulatory focus to mitigate the presence of these potential human carcinogens in drug substances and drug products.
<h5>Who Should Attend:</h5>
<ul>
<li>Anyone with an interest in, or challenged by, the analysis N-Nitrosamines and Nitrosamine Drug Substance Related Impurities (NDSRI) in API and/or Drug Products
</li>
<li>Analysts and Scientists working in the Pharmaceutical and Generic Pharmaceutical industries.
</li>
</ul>
<h5>Key Learning Points:</h5>
<ul>
<li>Review the latest regulatory updates (FDA and EMA)
</li>
<li>Learn about published LC-MS/MS applications which address the N-Nitrosamines and NDSRI analysis challenges in drug products
</li>
<li>Find solutions to sample preparation challenges for N-Nitrosamines analysis in drug products
</li>
<li>Obtain examples of specific Phenomenex applications for nitrosamines (10 mutagenic nitrosamine impurities in Acyclovir) and NDSRIs (N-nitroso propranolol in a propranolol drug substance and product)
</li>
</ul>
<blockquote>
Presenter: Phil Koerner (Market Development Manager, Pharmaceuticals)
</blockquote>

Phenomenex: Nitrosamines in Drug Products: Where Are We Now?

Nitrosamines in Drug Products: Where Are We Now?

Learn about published LC-MS/MS applications which address the N-Nitrosamines and NDSRI analysis challenges in drug products

LCMS webinars focusing on Consumables - page 11